Oxford Brain Diagnostics hopes to commercialise an early diagnosis tool for Alzheimer’s disease pioneered through eight years of University of Oxford research.
Oxford Brain Diagnostics, a UK-based neurodegenerative disorder diagnostics spinout from University of Oxford, today received an undisclosed amount of capital from university co-investment vehicle University of Oxford Innovation Fund (UOIF) IV.
UOIF IV is managed by Parkwalk Advisors, the fund management arm of commercialisation firm IP Group, on behalf of the university.
Founded in November 2018, Oxford Brain Diagnostics has devised an early diagnosis tool that could help predict whether patients suffering from mild memory issues will go…
